Cytosorbents (CTSO) Stock Forecast, Price Target & Predictions
CTSO Stock Forecast
Cytosorbents stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
CTSO Analyst Ratings
According to 1 Wall Street analysts, Cytosorbents's rating consensus is 'Buy'. The analyst rating breakdown for CTSO stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 29, 2024 | EF Hutton | - | Buy | Initialise |
Cytosorbents's last stock rating was published by EF Hutton on Jul 29, 2024. The company Initialise its CTSO rating from "null" to "Buy".
Cytosorbents Financial Forecast
Cytosorbents Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $8.67M | $8.81M | $9.42M | $7.91M | $7.64M | $6.46M | $7.33M | $7.92M | $9.70M | $8.90M | $11.37M | $10.14M | $11.53M | $10.25M | $9.52M | $8.16M | $6.61M | $5.73M | $5.85M | $4.58M | $4.43M | $2.60M |
| Avg Forecast | $13.40M | $12.90M | $11.90M | $11.40M | $9.80M | $9.94M | $9.68M | $9.80M | $9.28M | $9.50M | $11.03M | $8.74M | $8.54M | $8.97M | $9.58M | $9.72M | $9.68M | $9.70M | $12.27M | $11.51M | $11.75M | $9.49M | $9.62M | $6.96M | $6.93M | $6.55M | $6.38M | $6.17M | $5.90M | $5.60M |
| High Forecast | $14.20M | $13.67M | $12.61M | $12.08M | $10.39M | $10.64M | $10.26M | $10.38M | $10.28M | $10.07M | $11.68M | $9.26M | $9.05M | $9.50M | $10.20M | $10.35M | $10.31M | $10.33M | $13.07M | $12.26M | $12.51M | $10.11M | $10.24M | $7.41M | $7.38M | $6.98M | $6.80M | $6.58M | $7.08M | $6.72M |
| Low Forecast | $12.29M | $11.83M | $10.92M | $10.46M | $8.99M | $9.23M | $8.88M | $8.99M | $7.59M | $8.72M | $10.11M | $8.02M | $7.83M | $8.23M | $8.84M | $8.97M | $8.93M | $8.95M | $11.32M | $10.62M | $10.84M | $8.76M | $8.87M | $6.42M | $6.39M | $6.05M | $5.89M | $5.70M | $4.72M | $4.48M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | 0.93% | 0.93% | 0.85% | 0.90% | 0.89% | 0.72% | 0.77% | 0.82% | 1.00% | 0.92% | 0.93% | 0.88% | 0.98% | 1.08% | 0.99% | 1.17% | 0.95% | 0.87% | 0.92% | 0.74% | 0.75% | 0.46% |
Cytosorbents's average Quarter revenue forecast for Mar 24 based on 2 analysts is $9.80M, with a low forecast of $8.99M, and a high forecast of $10.38M. CTSO's average Quarter revenue forecast represents a 13.06% increase compared to the company's last Quarter revenue of $8.67M (Dec 23).
Cytosorbents EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | $-8.37M | $-7.35M | $-6.56M | $-8.55M | $-10.60M | $-5.51M | $-5.54M | $-6.30M | $-9.43M | $-6.17M | $-4.55M | $-4.00M | $-1.28M | $-423.98K | $-2.43M | $-2.97M | $-4.56M | $-6.44M | $-3.20M | $-4.54M | $-2.69M | $-1.31M |
| Avg Forecast | $-9.04M | $-8.71M | $-8.03M | $-7.69M | $-6.62M | $-6.71M | $-6.53M | $-6.61M | $-6.26M | $-6.41M | $-7.44M | $-5.90M | $-5.76M | $-4.33M | $-6.46M | $-8.00M | $-6.53M | $-6.55M | $-8.28M | $-5.34M | $-7.93M | $-6.41M | $-6.49M | $-3.65M | $-4.67M | $-4.42M | $-4.31M | $-5.30M | $-3.13M | $-1.71M |
| High Forecast | $-8.29M | $-7.98M | $-7.37M | $-7.06M | $-6.07M | $-6.23M | $-5.99M | $-6.07M | $-5.12M | $-5.88M | $-6.83M | $-5.41M | $-5.29M | $-3.46M | $-5.96M | $-6.40M | $-6.03M | $-6.04M | $-7.64M | $-4.27M | $-7.32M | $-5.91M | $-5.99M | $-2.92M | $-4.31M | $-4.08M | $-3.97M | $-4.24M | $-2.51M | $-1.37M |
| Low Forecast | $-9.58M | $-9.22M | $-8.51M | $-8.15M | $-7.01M | $-7.18M | $-6.92M | $-7.01M | $-6.94M | $-6.79M | $-7.88M | $-6.25M | $-6.11M | $-5.19M | $-6.88M | $-9.61M | $-6.96M | $-6.97M | $-8.82M | $-6.40M | $-8.45M | $-6.82M | $-6.91M | $-4.38M | $-4.98M | $-4.71M | $-4.59M | $-6.36M | $-3.76M | $-2.05M |
| Surprise % | - | - | - | - | - | - | - | - | 1.34% | 1.15% | 0.88% | 1.45% | 1.84% | 1.27% | 0.86% | 0.79% | 1.44% | 0.94% | 0.55% | 0.75% | 0.16% | 0.07% | 0.38% | 0.81% | 0.98% | 1.46% | 0.74% | 0.86% | 0.86% | 0.77% |
undefined analysts predict CTSO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cytosorbents's previous annual EBITDA (undefined) of $NaN.
Cytosorbents Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 11 |
| Net Income | - | - | - | - | - | - | - | - | $-5.83M | $-9.19M | $-6.15M | $-6.76M | $-766.13K | $-12.15M | $-10.86M | $-8.96M | $-9.31M | $-6.39M | $-4.66M | $-5.48M | $-677.72K | $280.19K | $-2.44M | $-4.43M | $-3.95M | $-8.14M | $-3.46M | $-5.48M | $-2.86M | $-1.20M |
| Avg Forecast | $-1.63M | $-1.63M | $-1.09M | $-1.09M | $-3.44M | $-3.62M | $-5.29M | $-6.52M | $-7.47M | $-6.70M | $-6.15M | $-6.88M | $-9.50M | $-4.49M | $-7.26M | $-8.27M | $-6.81M | $-6.60M | $-2.72M | $-5.56M | $-2.18M | $-5.20M | $-4.53M | $-4.25M | $-8.91M | $-7.33M | $-7.33M | $-5.70M | $-3.48M | $-1.79M |
| High Forecast | $-1.45M | $-1.45M | $-969.29K | $-969.29K | $-3.07M | $-2.59M | $-4.73M | $-5.82M | $-4.27M | $-5.98M | $-5.49M | $-6.14M | $-8.48M | $-3.59M | $-6.53M | $-6.62M | $-6.12M | $-5.94M | $-2.44M | $-4.45M | $-1.96M | $-4.68M | $-4.07M | $-3.40M | $-8.01M | $-6.60M | $-6.60M | $-4.56M | $-2.78M | $-1.43M |
| Low Forecast | $-1.76M | $-1.76M | $-1.17M | $-1.17M | $-3.71M | $-4.65M | $-5.70M | $-7.02M | $-11.73M | $-7.22M | $-6.62M | $-7.41M | $-10.24M | $-5.39M | $-7.87M | $-9.93M | $-7.38M | $-7.16M | $-2.94M | $-6.67M | $-2.36M | $-5.64M | $-4.91M | $-5.10M | $-9.66M | $-7.95M | $-7.95M | $-6.84M | $-4.17M | $-2.15M |
| Surprise % | - | - | - | - | - | - | - | - | 0.78% | 1.37% | 1.00% | 0.98% | 0.08% | 2.71% | 1.49% | 1.08% | 1.37% | 0.97% | 1.72% | 0.99% | 0.31% | -0.05% | 0.54% | 1.04% | 0.44% | 1.11% | 0.47% | 0.96% | 0.82% | 0.67% |
Cytosorbents's average Quarter net income forecast for Dec 20 is $-2.18M, with a range of $-2.36M to $-1.96M. CTSO's average Quarter net income forecast represents a -876.63% decrease compared to the company's last Quarter net income of $280.19K (Sep 20).
Cytosorbents SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 11 |
| SG&A | - | - | - | - | - | - | - | - | $9.24M | $8.10M | $7.72M | $9.13M | $8.71M | $9.34M | $9.12M | $9.96M | $11.08M | $8.44M | $10.54M | $8.42M | $9.38M | $7.86M | $7.44M | $6.84M | $7.21M | $6.84M | $5.10M | $5.32M | $4.68M | $2.95M |
| Avg Forecast | $13.46M | $12.96M | $11.95M | $11.45M | $9.85M | $9.98M | $9.72M | $9.84M | $9.32M | $9.55M | $11.08M | $8.78M | $8.58M | $5.92M | $9.62M | $9.19M | $9.72M | $9.74M | $12.32M | $11.22M | $11.80M | $9.53M | $9.66M | $6.99M | $6.96M | $6.58M | $6.41M | $6.20M | $5.46M | $3.83M |
| High Forecast | $14.26M | $13.73M | $12.66M | $12.13M | $10.43M | $10.69M | $10.30M | $10.43M | $10.33M | $10.11M | $11.73M | $9.30M | $9.09M | $7.10M | $10.24M | $11.03M | $10.36M | $10.38M | $13.12M | $13.47M | $12.57M | $10.15M | $10.29M | $7.45M | $7.41M | $7.01M | $6.83M | $6.61M | $6.55M | $4.60M |
| Low Forecast | $12.35M | $11.88M | $10.96M | $10.50M | $9.03M | $9.27M | $8.92M | $9.03M | $7.62M | $8.76M | $10.16M | $8.05M | $7.87M | $4.74M | $8.88M | $7.35M | $8.97M | $8.99M | $11.37M | $8.98M | $10.89M | $8.80M | $8.91M | $6.45M | $6.42M | $6.07M | $5.92M | $5.72M | $4.37M | $3.06M |
| Surprise % | - | - | - | - | - | - | - | - | 0.99% | 0.85% | 0.70% | 1.04% | 1.02% | 1.58% | 0.95% | 1.08% | 1.14% | 0.87% | 0.86% | 0.75% | 0.79% | 0.82% | 0.77% | 0.98% | 1.04% | 1.04% | 0.80% | 0.86% | 0.86% | 0.77% |
Cytosorbents's average Quarter SG&A projection for Mar 24 is $9.84M, based on 2 Wall Street analysts, with a range of $9.03M to $10.43M. The forecast indicates a 6.51% rise compared to CTSO last annual SG&A of $9.24M (Dec 23).
Cytosorbents EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 11 |
| EPS | - | - | - | - | - | - | - | - | $-0.12 | $-0.21 | $-0.14 | $-0.15 | $-0.02 | $-0.28 | $-0.25 | $-0.21 | $-0.21 | $-0.15 | $-0.11 | $-0.13 | $-0.02 | $0.01 | $-0.07 | $-0.13 | $-0.12 | $-0.25 | $-0.11 | $-0.17 | $-0.10 | $-0.05 |
| Avg Forecast | $-0.03 | $-0.03 | $-0.02 | $-0.02 | $-0.06 | $-0.07 | $-0.10 | $-0.12 | $-0.14 | $-0.12 | $-0.11 | $-0.13 | $-0.17 | $-0.17 | $-0.13 | $-0.14 | $-0.13 | $-0.12 | $-0.05 | $-0.04 | $-0.04 | $-0.10 | $-0.08 | $-0.14 | $-0.16 | $-0.14 | $-0.14 | $-0.18 | $-0.14 | $-0.12 |
| High Forecast | $-0.03 | $-0.03 | $-0.02 | $-0.02 | $-0.06 | $-0.05 | $-0.09 | $-0.11 | $-0.08 | $-0.11 | $-0.10 | $-0.11 | $-0.16 | $-0.15 | $-0.12 | $-0.13 | $-0.11 | $-0.11 | $-0.04 | $-0.03 | $-0.04 | $-0.09 | $-0.07 | $-0.12 | $-0.15 | $-0.12 | $-0.12 | $-0.16 | $-0.11 | $-0.09 |
| Low Forecast | $-0.03 | $-0.03 | $-0.02 | $-0.02 | $-0.07 | $-0.09 | $-0.11 | $-0.13 | $-0.22 | $-0.13 | $-0.12 | $-0.14 | $-0.19 | $-0.18 | $-0.15 | $-0.16 | $-0.14 | $-0.13 | $-0.05 | $-0.04 | $-0.04 | $-0.10 | $-0.09 | $-0.15 | $-0.18 | $-0.15 | $-0.15 | $-0.20 | $-0.17 | $-0.14 |
| Surprise % | - | - | - | - | - | - | - | - | 0.87% | 1.70% | 1.24% | 1.18% | 0.11% | 1.70% | 1.87% | 1.46% | 1.68% | 1.23% | 2.20% | 3.71% | 0.41% | -0.07% | 0.80% | 0.96% | 0.73% | 1.85% | 0.81% | 0.94% | 0.70% | 0.39% |
According to 9 Wall Street analysts, Cytosorbents's projected average Quarter EPS for Dec 20 is $-0.04, with a low estimate of $-0.04 and a high estimate of $-0.04. This represents a -698.06% decrease compared to CTSO previous annual EPS of $0.01 (Sep 20).
Cytosorbents Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| APYX | Apyx Medical | $1.08 | $8.50 | 687.04% | Buy |
| CTSO | Cytosorbents | $1.32 | $9.00 | 581.82% | - |
| TELA | TELA Bio | $2.56 | $14.00 | 446.88% | Buy |
| INGN | Inogen | $10.84 | $26.00 | 139.85% | Buy |
| OFIX | Orthofix Medical | $16.22 | $31.00 | 91.12% | - |
| CVRX | CVRx | $8.50 | $15.83 | 86.24% | Buy |
| NPCE | NeuroPace | $6.96 | $12.88 | 85.06% | Buy |
| FNA | Paragon 28 | $6.94 | $11.50 | 65.71% | Buy |
| LUNG | Pulmonx | $8.18 | $12.25 | 49.76% | Buy |
| LIVN | LivaNova | $51.00 | $70.20 | 37.65% | Buy |
| KIDS | OrthoPediatrics | $31.08 | $40.80 | 31.27% | Buy |
| AORT | Artivion | $25.22 | $30.00 | 18.95% | Buy |
| CLPT | ClearPoint Neuro | $11.92 | $12.00 | 0.67% | Buy |
| SRDX | Surmodics | $39.26 | $39.50 | 0.61% | Buy |
CTSO Forecast FAQ
Is Cytosorbents a good buy?
Yes, according to 1 Wall Street analysts, Cytosorbents (CTSO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of CTSO's total ratings.
What are Cytosorbents's analysts' financial forecasts?
Cytosorbents's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $39.22M (high $41.67M, low $36.09M), average EBITDA is $-26.47M (high $-24.355M, low $-28.119M), average net income is $-18.871M (high $-16.196M, low $-21.086M), average SG&A $39.4M (high $41.85M, low $36.25M), and average EPS is $-0.348 (high $-0.298, low $-0.388). CTSO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $49.6M (high $52.55M, low $45.5M), average EBITDA is $-33.471M (high $-30.701M, low $-35.464M), average net income is $-5.431M (high $-4.846M, low $-5.851M), average SG&A $49.82M (high $52.79M, low $45.7M), and average EPS is $-0.1 (high $-0.0892, low $-0.108).
Did the CTSO's actual financial results beat the analysts' financial forecasts?
Based on Cytosorbents's last annual report (Dec 2023), the company's revenue was $36.35T, beating the average analysts forecast of $38.55M by 94302882.94%. Apple's EBITDA was $-31.209T, beating the average prediction of $-26.011M by 119984213.63%. The company's net income was $-28.507T, beating the average estimation of $-27.19M by 104845245.97%. Apple's SG&A was $33.6T, beating the average forecast of $38.72M by 86786040.82%. Lastly, the company's EPS was $-0.64, beating the average prediction of $-0.501 by 27.83%. In terms of the last quarterly report (Dec 2023), Cytosorbents's revenue was $8.67M, missing the average analysts' forecast of $9.28M by -6.54%. The company's EBITDA was $-8.369M, beating the average prediction of $-6.259M by 33.71%. Cytosorbents's net income was $-5.835M, missing the average estimation of $-7.467M by -21.86%. The company's SG&A was $9.24M, missing the average forecast of $9.32M by -0.80%. Lastly, the company's EPS was $-0.12, missing the average prediction of $-0.138 by -12.73%